Correspondence | Published:

Should we ignore western blots when selecting antibodies for other applications?

Nature Methods volume 14, page 215 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nat. Methods 13, 823–827 (2016).

  2. 2.

    , , & Biotechniques 55, 111–114 (2013).

  3. 3.

    et al. Blood 107, 1892–1895 (2006).

  4. 4.

    , & Naunyn Schmiedebergs Arch. Pharmacol. 379, 409–412 (2009).

  5. 5.

    et al. EMBO Rep. 14, 10–11 (2013).

  6. 6.

    et al. Histopathology 60 6B, E37–E50 (2012).

Download references

Acknowledgements

F.L.-J. receives funding from the K G Jebsen Foundation.

Author information

Affiliations

  1. K G Jebsen Center for Cancer Immunotherapy, Oslo University Hospital, Oslo, Norway.

    • Fridtjof Lund-Johansen
  2. Department of Immunology, Oslo University Hospital, Oslo, Norway.

    • Fridtjof Lund-Johansen
  3. PhosphoSolutions, Colorado Bioscience Park, Aurora, Colorado, USA.

    • Michael D Browning

Authors

  1. Search for Fridtjof Lund-Johansen in:

  2. Search for Michael D Browning in:

Competing interests

M.D.B. is owner and CEO of PhosphoSolutions, which manufactures antibodies for use in research.

Corresponding author

Correspondence to Fridtjof Lund-Johansen.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nmeth.4192

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing